Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
PD-(L)1 x VEGF bispecifics prove a big draw.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.